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Abstract  
Purpose of review   
Complicated intra-abdominal infections (cIAIs) are associated with significant morbidity and mortality. 
Clinical trials should help guide and improve the management of cIAIs.  However, inappropriate 
selection or measurement of outcomes in cIAIs clinical trials can lead to misleading results on the 
effectiveness of interventions. This review aims to describe how outcomes are reported in randomised 
controlled trials (RCTs) evaluating antibiotic treatment for cIAIs and discuss how outcome reporting 
may be improved. 
Recent findings 
Commonly used primary outcomes are treatment success or failure, these outcomes are endorsed by 
regulatory bodies. However, a consensus objective definition of either is not available and current 
measures are prone to bias. Variation exists in timing of outcome evaluation and analysis populations 
which can lead to further bias. Use of core outcome sets (COS) can help standardise outcome reporting.  
Summary 
Inconsistency in outcome selection and reporting can lead to misleading results and impedes meta-
analysis of data. Further progress, engaging clinical trialists, regulatory authorities, clinicians and 
patients is required to achieve consensus on which outcomes should be reported and how and when 
to measure them.  
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Key Points 
 There are variations in the selection and measurements of outcomes in clinical trials assessing 
antibiotics and antibiotic treatment strategies for complicated intra-abdominal infections 
(cIAIs).   
 These variations can lead to difficulty in interpreting trial results and impedes comparison of 
different studies. 
 Development of a core outcome set to be used in cIAIs trials, will standardise the outcome 
used and lead to higher quality evidence generation, enabling to clinicians to make better 
decisions on the management of cIAIs. 
 
Introduction 
Complicated intra-abdominal infections (cIAIs) are intra-abdominal infections that have extended 
beyond the organ of origin causing either abscess formation and/or peritonitis (1). They are the second 
commonest cause of sepsis in patients on intensive care units (2, 3).  A recent six month prospective 
study of cIAIs worldwide reported a 10.5% mortality in patients with cIAIs (4).  Management of cIAIs 
includes controlling the source of infection (through either a surgical procedure or percutaneous 
drainage of an abscess) plus systemic antibiotic therapy.  As resistance to commonly used antibiotics 
in cIAIs rises, clinical trials assessing the effectiveness of new antibiotics for cIAIs are essential.   
Outcome measures are used in research to help to determine the comparative efficacy of different 
interventions and treatments. However, while the choice of outcomes often seem obvious to clinicians 
(e.g. failure of treatment), it is in practice a difficult challenge to define clear, reproducible and widely 
agreed outcomes.  This matters, as unsuitable or poorly defined outcomes could lead to inappropriate 
conclusions about the safety and/or efficacy of an intervention. It is also well recognised that 
inconsistent and incomplete outcome reporting is common, making the interpretation of the 
effectiveness of different interventions difficult (5). Additionally, consistent outcomes are needed to 
allow meta-analyses to be performed.  To ensure consistent outcomes are collected in randomised 
clinical trials (RCTs), it is recommended a set of core outcomes should be collected (6). Core outcomes 
are an agreed minimum number of outcomes that should be reported in all trials for a specific 
condition.  Initiatives such as COMET (Core Outcome Measures in Effectiveness Trials) provides a 
resource to search for developed and in preparation core outcome sets (6).  
In antibiotic trials for complicated intra-abdominal infections, the dichotomous outcome of 
cure/failure is often reported. Hﾗ┘W┗Wヴが ; IﾗﾐゲWﾐゲ┌ゲ SWaｷﾐｷデｷﾗﾐ ﾗa けI┌ヴWげ SﾗWゲ ﾐﾗデ W┝ｷゲデ ;ﾐS ｷデ ｷゲ ﾗaデWﾐ 
based on subjective measures.  Additionally, these dichotomous outcomes are of limited value as they 
Sﾗ ﾐﾗデ デ;ﾆW ｷﾐデﾗ ;IIﾗ┌ﾐデ ; ヮ;デｷWﾐデげゲ ｪﾉﾗH;ﾉ W┝ヮWヴｷWﾐIW ﾗa HWﾐWaｷデゲ ;ﾐS ｴ;ヴﾏゲ, as well as the impact on 
quality of life.  Furthermore, when, how, and in which analysis population outcomes are measured 
need to be considered, otherwise there is  considerable scope for bias and inaccurate conclusions of 
management efficacy and safety. 
This review summarises the current recommended outcomes and the outcomes measured in recent 
and landmark trials assessing antibiotic treatment for complicated intra-abdominal infections. 
Recommendations on future measures to improve outcome reporting in cIAIs are also provided.  
Outcome selection 
In 1990, Nystrom et al. proposed a set of outcomes to be used in clinical trials of the management of 
intra-abdominal infections (7).  The proposed primary outcomes were mortality and time to recovery.  
They define recovery as restoration of normal physiology (as indicated by a acute physiology score), a 
temperature <37.8oC for 24 hours, restoration of gastrointestinal function (as demonstrated by ability 
to tolerate an oral diet), return of gastrointestinal motor activity (as indicated by passing of flatus or 
faeces) and that the patient is alert and orientated (or returned to baseline).  The authors stated that 
time to recovery is preferred over the more subjective measures of cured, improved or failed 
outcomes, as it is objective and easily measurable using the above criteria. 
The Food and Drug Administeration (FDA) and European Medicines Agency (EMA) require antibiotic 
efficacy trials, which aim to generate evidence for the approval of a new agent, to report on specific 
outcomes, as outlined in their respective guidelines (8, 9). In the FDA guidance, it is recommended 
that clinical success or failure should be assessed as primary outcomes, with assessments up until day 
28 post randomisation (8).  Clinic;ﾉ ゲ┌IIWゲゲ ｷゲ SWaｷﾐWS ;ゲ デｴW けヴWゲﾗﾉ┌デｷﾗﾐ ﾗa H;ゲWﾉｷﾐW ゲｷｪﾐゲ ;ﾐS ゲ┞ﾏヮデﾗﾏゲげ 
based on objective measures.  Clinical failure is classed as either death, the need for a unplanned 
surgical procedure, an extra-abdominal infection, surgical site infection (SSI) or relapse (or worsening) 
of cIAI.  The EMA recommends that clinical outcome, categorised as cure, failure or indeterminant, 
should be reported as the primary outcome.  Cure is described as the complete resolution of clinical 
signs and symptoms; however, it is not specified which parameters should be measured, but that 
outcome evaluation should occur at an appropriately timed test of cure (TOC) visit (9).   
Different analysis populations are used to report outcomes in clinical trials of cIAIs treatments.  
Commonly used analysis populations include the modified intention to treat (mITT) population 
(defined as all trial participants who received the intervention), clinically evaluable (CE) population 
(which generally includes patients who have received the intervention as per protocol and adhered to 
all study procedures) and the microbiological intention to treat (micro-ITT) population (which includes 
participants who fulfil CE criteria and who also have a baseline bacterial pathogen known to cause cIAI) 
(10).  The FDA and EMA both now suggest that the micro-ITT should be used as the primary analysis 
population (8, 9).  Analysis of specific populations can lead to bias as it excludes some patients, and so 
may fail to retain the balance of participant numbers in each trial arm created by baseline 
randomisation. However, where ITT populations are very similar to the CE, mITT and micro-ITT 
populations the risk of bias is negligible (10).  
More recently, the potential merits of an innovative outcome ranking (DOOR) scale for evaluating 
treatment outcomes for antibiotic studies have been described (11).  This ordinal scale (i.e. the second 
level of measurement that reports the ranking and ordering of data without actually establishing the 
degree of variation between them) categorises participants into clinical outcomes based on both the 
benefits and harms they experience, and then ranks these according to the desirability of each 
outcome.  Higher ranks are assigned to participants with better clinical outcomes.  The benefit of using 
DOOR is that it attempts to analyse a ヮ;デｷWﾐデげゲ global experience by combining efficacy and safety 
outcomes (12).  DOOR can be used with デｴW けresponse adjusted for duration of antibiotic riskげ (RADAR), 
which is a tool to measure antibiotic use.  Like DOOR, it has an ordinal scale and it assumes that shorter 
antibiotic courses are superior.  Participants in each DOOR category are further ranked based on their 
RADAR score.  Finally, the probability that a participant will have a better DOOR/RADAR score if 
assigned to the intervention arm is then calculated. Celestin et al, in a post hoc analysis applied 
DOOR/RADAR to data from the STOP IT trial, which evaluated antibiotic duration for cIAIs; short course 
antibiotics were found to be superior to longer courses (13, 14). However, selection of the 
DOOR/RADAR components is subjective and may differ between trials. Furthermore, studies have 
found that the final DOOR/RADAR scores are influenced by the number of clinical outcome categories 
(11, 13, 15). Therefore, it is important that these categories are selected carefully a-priori via a 
consensus process.   
Current guidance fails to identify the best approach to selecting and measuring outcomes.  The FDA 
and EMA guidelines do not offer guidance on how to measure treatment success, therefore different 
parameters may be used by different trialists.  Alternatively, Nystrom et al, suggest using time to cure 
as an objective measure of treatment success however this is not utilised (16-19). Although, 
DOOR/RADAR is an alternative to traditional binary outcomes, its role in cIAIs trials needs further 
review.    
Currently reported outcomes 
In 2017, IGNITE 1, a randomised control trial (RCT) that compared the novel synthetic tetracycline 
evracycline with ertapenem, the primary outcome used was clinical response (clinical cure, failure or 
indeterminate) in the micro-ITT group at the TOC visit performed 25-31 days after randomisation 
(16).Cure was defined as the complete resolution or significant improvement in all signs and 
symptoms of the index infection such that no further antibiotics or intervention was required.  Failure 
was defined as either death related to cIAI at any time, the persistence of signs or symptoms, 
unplanned procedures, SSI or the initiation of additional antibiotics for cIAI.  The primary outcomes 
were reported in modified-ITT, CE and micro-ITT populations in order to comply with regulatory 
guidance.  IGNITE 4 (2018) compared evracycline with meropenem, this trial design was similar to 
IGNITE 1 and the same outcome measures were used (17). Qin et al (2017), similarly used clinical 
response as the primary efficacy outcome in their RCT comparing ceftazidime/avibactam plus 
metronidazole with meropenem in patients with cIAIs in Asia (18).  The analysis population was the 
clinically evaluable (CE) population with outcome assessments occurring 28-35 days after 
randomisation.  In a multicentre RCT comparing tigecycline with imipenem/cilastatin to treat cIAIs, 
Chen et al (2018) also used the CE population as the primary analysis population to report their 
primary outcome of clinical cure, which was assessed at the TOC visit performed between 14 - 21 days 
after end of treatment (EOT) (19).  Evidently, each of these studies assessed outcomes at different 
time points (14-21 days vs 25-31 days vs 28-35 day), and   such inconsistency could lead to bias. 
The landmark STOP IT trial published in 2015 compared short course (4 days +/- 1 day) with long course 
ふг ヱヰ S;┞ゲぶ ;ﾐデｷHｷﾗデｷIゲ for cIAIs (14).  Ongoing signs of a systemic inflammatory response (SIRS) in the 
group who received short course antibiotic was not indicative of clinical failure, and instead was 
suggested by the investigators to be a marker of host immune activity.  Thus, using resolution of 
symptoms and signs could be an unreliable marker of clinical response.  This RCT was the first to assess 
antibiotic duration for cIAIs.  The primary outcome was a composite consisting of SSI, recurrent cIAI, 
or death occurring within 30 days of the primary source control procedure.  In a subsequent RCT 
evaluating antibiotic duration for patients with post-operative cIAIs, the DURAPOP trial (2018), the 
investigators used antibiotic free days as assessed on day 28 as the primary outcome (20). Although 
antibiotic free days can be a proxy marker for efficacy, it is not a patient centred outcome. Initially 
there were two proposed primary outcomes (antibiotic free days between days 8 and 45 and mortality 
between days 8 and 45). However, due to low recruitment rates this was switched to a single outcome, 
thus illustrating how the choice of outcomes measured can be affected by study design.  
Conclusion 
There are variations in the outcomes used in antimicrobial trials for cIAI, as well as how and in whom 
these are assessed.  Albeit potentially subtle, such differences have the potential to lead to bias 
resulting in misleading results and failure to find the best treatment to improve ヮ;デｷWﾐデゲげ quality of 
life.  This, coupled with the lack of objective and validated definitions, means that the current 
outcomes used in cIAIs are flawed.   The development and implementation of standardised outcomes, 
so called けcore outcome setsげ, that are clinically meaningful would allow a more accurate 
understanding the effectiveness of different treatments for cIAIs. This would enable clinicians to make 
better decisions on patient care, and result in improved antimicrobial prescribing and patient 
experience. Regulatory bodies should promote the development of core outcome sets for use in future 
clinical trials.  
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